Tachibana provided third quarter 2025 guidance of total company revenue in the range of $12 million to $14 million and pharma test/services revenue in the range of $11 million to $13 million.

Fourth quarter revenue is expected to be about $4 million or 3.5% lower than Q3, driven by systems revenue. "Our guidance for Q4 revenue was approximately $122 million, plus or minus $7 million. The ...

GeneDx raised full year 2025 total revenue guidance to $425 million to $428 million. Exome and genome revenue guidance was increased to $358 million to $361 million, reflecting 53% to 55% growth for ...